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In a recent work by our group involving a transcriptomics approach applied to the venom glands from
Tityus stigmurus we identiﬁed a new family of peptides called Hypotensins (TSTI0006C) (Almeida et al.,
2012). The cluster TSTI0006C was analyzed in the main 25 amino acid residues and named T. stigmurus
Hypotensin (TistH), showing a molecular mass of 2.7 kDa, an absence of cysteines and the presence of
two C-terminal proline residues, which are a bradykinin-potentiating peptide (BPP) signature. Here, we
describe the homology modeling of the three-dimensional structure of TistH. In addition, we evaluated
the cardiovascular effects elicited by TistH in normotensive rats. Firstly, TistH showed no cytotoxic effect
on horse erythrocyte. Furthermore, in normotensive rats TistH was able to potentiate the hypotensive
action of bradykinin (BK) and induced a vasorelaxant effect in mesenteric artery rings by endothelium-
dependent release of nitric oxide (NO) and demonstrated independent inhibition of angiotensin con-
verting enzyme (ACE). Our data can contribute to a better understanding of the structural and functional
characteristics of TistH and suggest its potential use in cardiovascular diseases.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
The scorpion Tityus stigmurus belongs to the Buthidae family, it
appears predominantly in Northeast Brazil and is known for a high
incidence of envenoming in humans (Almeida et al., 2012; Batista
et al., 2007). Scorpion venoms are rich sources of small peptide
toxins (Alves et al., 2013). These toxins are responsible for the
pathogenesis of scorpion because of its highly speciﬁc interaction
with proteins of the membrane ion channel. This arsenal of toxins
can be used for many purposes including prey capture and defense
(Du Plessis et al., 2008; Guo et al., 2013). Because of its speciﬁcityio Grande do Norte, Av. Gal.
zil.
es-Pedrosa).and high afﬁnity, scorpion toxins have been used as pharmaco-
logical tools worldwide (Du Plessis et al., 2008).
Several components of the scorpion venom act on the cardio-
vascular system. These include natriuretic peptides, which are
important regulators of the cardiovascular and renal system; the
sarafotoxins, which are major vasoconstrictor peptides; and
bradykinin-potentiating peptides (BPPs), which are peptides with
hypotensive properties that have been previously described in the
literature regarding venom of different animal groups (Hodgson
and Isbister, 2009; Yeow and Kini, 2012).
The molecular repertoire of the venom gland of the scorpion
T. stigmurus was elucidated by our group (Almeida et al., 2012),
which identiﬁed the presence of a variety of peptides of pharma-
cological interest, including hypotensins, antimicrobial peptides
(AMPs), toxins acting on potassium and sodium channels, as well as
ﬁve atypical types: lectins, metalloproteases, anionic peptides,
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(Almeida et al., 2012).
The ﬁrst bradykinin potentiating peptide (BPP) isolated from the
scorpion venom of the genus Tityus was obtained from Tityus ser-
rulatus and called peptide T (Ferreira et al., 1993). Recently, a new
family of hypotensins was identiﬁed in T. serrulatus venom and the
results showed that this new family does not inhibit angiotensin
converting enzyme (ACE) (Verano-Braga et al., 2008).
Bradykinin potentiating peptides previously described (Ferreira
et al., 1970) are low molecular weight peptides which potentiate
the pharmacological effect of bradykinin and may or may not
inhibit angiotensin converting enzyme (ACE), which is an essential
enzyme for the regulation of blood pressure (Verano-Braga et al.,
2010).
The BPPs are characterized by a high content of proline and have
a typical amino acid signature: an N-terminal pyroglutamic acid
and the sequence Ile-Pro-Pro at the C-terminal (Verano-Braga et al.,
2008). The research of these biological functions was essential for
the development of captopril, the ﬁrst commercial ACE inhibitor,
currently used in the treatment of hypertension, whose design was
based on one BPP isolated from Bothrops jararaca venom (Ondetti
et al., 1971; Verano-Braga et al., 2010).
A variety of population studies highlighted the importance of
controlling hypertension to reduce cardiovascular morbidity and
mortality. The development of modern technologies in relation to
medicines has contributed little to improve rates of disease control
(Maria et al., 2009). Thus peptides isolated from animal venoms
may be useful in developing new classes of antihypertensive drugs
in order to expand the range of therapies to control hypertension
(Lewis and Garcia, 2003).
In this context, the present study aimed to describe tridimen-
sional structure, vasorelaxant and bradykinin-potentiating activ-
ities and ACE inhibition of a new hypotensin called TistH (T.
stigmurus Hypotensin) deduced from the transcriptome of the
venom gland of T. stigmurus.
2. Methods
2.1. cDNA cloning and bioinformatic analyses
A full-length cDNA library was prepared using the In-Fusion™
SMARTer™ cDNA Library Construction Kit (CLONTECH Lab., Palo Alto,
CA) as described elsewhere (Almeida et al., 2012). The complete
nucleotide sequence with a close similarity to hypotensins
(TSTI0006C) was analyzed by ORF-Finder [http://www.ncbi.nlm.
nih.gov/projects/gorf/]. The mature peptide containing 25 amino
acid residues was deduced by Vector NTI suite program (Informax).
The prediction of signal cleavage sites was performed using the
SignalP 4.1 Server program and the mature peptide was aligned
using CLUSTALW.
2.2. Drugs and reagents
The cluster TSTI0006C obtained from T. stigmurus transcriptome
codes a peptide containing 25 amino acid (ADMDFTGIAESIIKKI-
KETNAKPPA; herein named TistH) showing a deduced molecular
mass of 2.7 kDa and the synthetic peptidewas customordered from
Invitrogen Life Technologies, USA. Bradykinin (BK), Hip-His-Leu,
orthophthaldehyde (OPA), L-NAME, phenylephrine, urethane and
Angiotensin-converting Enzyme I were purchased from Sigma-
eAldrich (St. Louis, EUA). Captopril was purchased from a manip-
ulation pharmacy in Natal-RN. The peptide Abz-FRK(Dnp)PeOH
was provided by Prof. Adriana K. Carmona, from the Department of
Biophysics of UNIFESP-EPM and BPP Xc was synthesized by Genone
Biotechnologies.2.3. Animals
Wistar rats weighing 200e300 g were obtained from the
Biotechnology Center of the Federal University of Paraiba. The an-
imals were acclimated with four animals per cage and maintained
under photoperiod of 12/12 h, at 21 ± 1 C temperature, with access
to food (Labina®, Purina, S~ao Paulo, Brazil) and water ad libitum. All
procedures described in the present study are in agreement with
Institutional Animal Care and Use Committee of the Federal Uni-
versity of Paraiba (CEPA/LTF protocol n 0305/09).
2.4. Homology modeling
In order to ﬁnd homologous sequences with 3D structures the
BLAST program templates (Altschul et al., 1990) were used with the
NCBI protein Data Bank (PDB) database using TistH sequence as a
query sequence. According to the BLAST results, ﬁve templates
were downloaded from the RCSB Protein Data Bank (Bernstein
et al., 1977): X-ray structure dihydrofolate reductase/thymidylate
synthase from Babesia bovis at 2.35 Å resolution (PDB ID: 3I3R,
Chain A) (Begley et al., 2011); Coecrystal structure of dihydrofolate
reductase-thymidylate synthase from B. bovis with dUMP, Rali-
trexed and NADP (PDB ID: 3NRR, Chain A) (Begley et al., 2011);
Structure of S. aureus methicillin resistance factor MecR2 (PDB ID:
4IJA, Chain A) (Are^de et al., 2013); Crystal Structure of an N-ter-
minal Fragment of SKAP-Hom containing Both the Dimerization
Domain and the PH Domain (PDB ID: 1U5E, Chain A) (Jiao et al.,
2013) (To be Published) and Triple mutant SFTAVN (PDB ID: 4J4S,
Chain A). The sequence alignments were performed with the
Clustal-W program server (Larkin et al., 2007).
Homology modeling of the TistH was constructed by four ho-
mology modeling programs such as MODELLER 9v13 (Sali and
Blundell, 1993), SWISS-MODEL (Schwede, 2003), Phyre2 Web
Server (Kelley and Sternberg, 2009) and I-TASSER (Roy et al., 2010).
250 theoretical models were generated in the MODELLER and 5 for
I-TASSER. It was not possible to generate theoretical models for the
Phyre2Web and SWISS-MODEL servers due to the requirement of a
minimum of 30 amino acid residues. The 3D models generated by
theMODELLERwere ranked based onmolecular probability density
function (Molpdf). The best scored MODELLER and I-TASSER
models were validated by the evaluation of the F/j Ramachandran
plot (Lovell et al., 2003) employing PROCHECK algorithms
(Laskowski et al., 1993), QMEAN score (Benkert et al., 2008) and the
MolProbity program (Chen et al., 2010). The models were analyzed
and sorted by score values, and visualized using a Visual Molecular
Dynamics (VMD) program (Humphrey et al., 1996). The best models
were submitted to a molecular dynamics analysis for further
reﬁnement.
2.5. Molecular dynamics
Themolecular dynamics were performed by the GROMACS 4.6.5
program (Van Der Spoel et al., 2005) in order to reﬁne the obtained
homology models by using three different force ﬁelds for each
model: AMBER-03 (Duan et al., 2003), CHARMM (Brooks and
Bruccoleri, 1983) and GROMOS96 43a1 (Scott et al., 1999). For
AMBER-3 and CHARMM an explicit TIP3P water model (Jorgensen
et al., 1983) was used and for GROMOS96 43a1, an SPC model
(Toukan and Rahman, 1985). Enough Naþ and Cl counter ions were
added to neutralize the system. The simulations were performed in
a rhombic dodecahedron box with a 1.2 nm minimal distance be-
tween the peptide box walls. A bond was made using the LINCS
algorithm (Hess et al., 1997). Electrostatic forces were calculated
with the PME (Darden et al., 2014) implementation of the Ewald
summation method, and the LennardeJones interactions were
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the solvated peptide geometry was minimized twice by the
steepest descent algorithm for 5000 steps with tolerances of 1000
and 500 kJ mol1 nm1 followed by another two conjugated
gradient optimizations for 50,000 steps with tolerances of 250 and
100 kJ mol1 nm1. In order to accommodate the solvent to the
peptide, due to the great strain dissipated by the system, a 50-ps
molecular dynamics analysis at 300 K was performed where the
non-hydrogen atoms of the peptide were kept ﬁxed. Then, unre-
strained 50, 100 and 150-ps molecular dynamics simulations were
performed to couple the system to the heat bath using NVT
ensemble at a temperature of 310 K. Subsequently, 50, 100 and 150-
ps NPT ensemble molecular dynamics simulations were performed
to pressure control the system at a pressure of 1 bar using isotropic
pressure bath with Berendsen pressure coupling algorithm
(Berendsen et al., 1984). Finally, 50 ns production molecular dy-
namics simulations using NVT ensemble were performed in order
to assess the stability of the system. The root-mean-square devia-
tion (RMSD) between C-a of models was calculated to evaluate the
structural stability of the models. The models were also submitted
to semi-empirical calculation using Parameterization Method 6
(PM6).2.6. Parameterization Method 6 (PM6)
Quantum-mechanical techniques to calculate protein properties
such as: structure, energetics or interactions, are still very limited
due to the high computational cost of solving SCF equations, thus
limiting the size of the system to just a few hundred atoms. The
semi-empirical electronic structure method has emerged as a tool
for reducing the computational time in the treatment of molecular
systems containing a large number of atoms (Stewart, 1990). Thus,
these methods have been developed in order to treat chemical
problems involving electronic properties of large molecules which
cannot be treated by ab initiomethods. The semi-empirical method
PM6 (Parameterization Method 6) has shown good accuracy in
reproducing heat of formation (DHf) and geometries of small
molecules (Stewart, 2007), crystals (Stewart, 2008), nonapeptide
oxytocin (Stewart, 2008) and modeling of proteins (Stewart, 2009).
PM6 is based on the Neglect of Diatomic Differential Overlap
(NDDO) method (Pople et al., 1965), where the electronic energy of
the valence electrons is given by the Equation (1):
Eelectronic ¼
1
2
X
m
X
y
Pmy

Hmy þ Fmy

(1)
where Greek subscripts m and y are used to denote atomic orbitals
to atoms A or B, Fmy is the NDDO Fock matrix elements, Hmy and Pmy
are elements of the one-electron core Hamiltonian and the density
matrix, respectively. The total energy of the molecule is the sum of
its electronic energy (Eelectronic) and the repulsion energy (EcoreAB )
between cores of all atoms A and B (2):
Etotal ¼ Eelectronic þ
X
A
X
B
EcoreAB (2)
and ﬁnally, the heat of formation (DHformation) (Repasky et al., 2002)
is calculated (Equation (3)) by subtracting the electronic energy of
atom A (EAelectronic) of Etotal and adding the experimental heat of
formation for atom A (DHAformation).
DHformation ¼ Etotal 
X
A
EAelectronic þ
X
A
DHAformation (3)
In this work, the semi-empirical method PM6 incorporated intothe program MOPAC2012 (Stewart, 2012) was used to determine
the heat of formation (DHformation), electronic energy (Eelectronic) and
total energy (Etotal) of the models resulting from molecular dy-
namics in order to select the most stable model through single
point calculations.
2.7. Mass spectrometry analyses
The synthetic TistH was analyzed by MALDI-ToF MS/MS (Ultra-
Flex III, Bruker Daltonics, Billerica, MA) to ensure the quality of the
methods of synthesis and puriﬁcation.
2.8. Hemolytic activities
Hemolytic activity was measured by incubating increasing
concentrations of the TistH (1.0  1010e1.0  104 M) with a
suspension of 1% (v/v) horse erythrocytes previously separated
from the plasma by sedimentation and washed three times with
PBS (0.15 M, pH 7.4). A volume of 100 mL Triton X-100, 1% (v/v) was
also incubated with a suspension of erythrocytes, making a refer-
ence of 100% hemolysis. Incubation with 100 mL of 0.15 M PBS
buffer, pH 7.4 was the reference for 0% hemolysis. After 60 and
120 min of incubation at room temperature the tubes were
centrifuged at 8000g for 3 min and 100 mL aliquots of the super-
natants were transferred to 96-well microtiter plates and analyzed
in a plate reader with absorbance at 405 nm (Johansson et al.,
2002).
2.9. Surgical procedure
Polyethylene catheters (4 cm of PE-10 welded to the 17 cm
segment of PE-50) were inserted into the abdominal aorta and
femoral vein for blood pressure measurement and intravenous
drug administration, respectively. This catheter was closed by
metal pins and ﬁlled with isotonic saline. All procedures were
performed on rats anesthetized with urethane (1.2 g kg1, i.p.).
2.10. Cardiovascular measurements
Blood pressure and heart rate were recorded using a pressure
transducer (MLT0380/D, ADInstruments, Sydney, Australia)
coupled to an acquisition system (Powerlab, ADInstruments) con-
nected to a computer running the LabChart software
(ADInstruments).
2.11. Bradykinin-potentiation test on anaesthetized rat
Experiments were performed on normotensive Wistar rats
(200e300 g) according to a previously described procedure (Paula
et al., 1995). For the evaluation of the potentiating effect of brady-
kinin, rats were randomly divided into groups of ﬁve animals ac-
cording to the treatment being received. The hypotensive response
elicited by bradykinin was determined by the administration of
bradykinin (3e6 mg kg1, i.v.) at 10-min intervals. After evaluating
the effects on mean arterial pressure in response to bradykinin, a
single dose of the TistH at two concentrations (400 mg kg1 or
600 mg kg1 dissolved in 100 mL de NaCl 0.9%) was administered.
Then, successive administrations of BK (3 mg kg1) at regular in-
tervals (every 10 min) were performed, followed by measurement
of mean arterial pressure values to determine whether the hypo-
tensive effect of bradykininwas affected by the synthetic TistH. The
effect was considered to be caused by bradykinin-potentiating
peptide (BPP) when responses were greater than that caused by
administration of control BK (3 mg kg1). One group of animals
received captopril (150 mg kg1) in saline (NaCl 0.9%) as the default
Table 1
Percentage of identity and expect value (e-value) of templates using BLAST program.
Templates Identity (%) E-value
3I3Ra 50 1.2
3NRRb 50 1.2
4IJAc 73 1.6
1U5Ed 78 3.2
4J4Se 88 4.5
a X-ray structure dihydrofolate reductase/thymidylate synthase from Babesia
bovis at 2.35 Å resolution.
b Coecrystal structure of dihydrofolate reductase-thymidylate synthase from
Babesia bovis with dUMP, Ralitrexed and NADP.
c Structure of S. aureus methicillin resistance factor MecR2.
d Crystal Structure of an N-terminal Fragment of SKAP-Hom Containing Both the
Dimerization Domain and the PH Domain.
e Triple mutant SFTAVN.
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2.12. Mesenteric artery rings assay
Experimental procedures were performed as described by
França-Silva and cols (França-Silva et al., 2012). The vasorelaxant
effect of synthetic TistH is reported in mesenteric artery rings iso-
lated from normotensive rats (n ¼ 7). The rats were euthanized by
decapitation in guillotine, and through an incision in the abdomen,
mesenteric artery was identiﬁed, removed and immediately placed
in a Petri dish containing Tyrode's buffer nutrient solution and then
gassed with a gas mixture (95% O2 e 5% CO2) to maintain the pH
between 7.2 and 7.4. The vessel was dissected and sectioned into
rings (1e2 mm). Mesenteric artery rings were suspended vertically
by cotton yarn, put in tanks for isolated organ bath of up to 10 mL
(Automatic organ bath, system Panlab/Harvard Apparatus, USA)
and subjected to a constant tension of 0.75 g and temperature of
37 C. Preparation was allowed a stabilization period of 1 h and the
Tyrode buffer solution was replaced every 15 min to prevent
interference of metabolites. The tension was recorded via a force
transducer (PowerLab™, ADInstruments, Australia), coupled to a
data acquisition system (Larb chart 4). In some of the rings, the
endothelium was removed by mechanical friction between the
inner wall of the vessel and a stainless steel rod. After the stabili-
zation period, the presence of functional endothelium was veriﬁed
by the relaxation of rings pre-contracted with phenylephrine
(105 M) after the addition of acetylcholine (105 M). Rings with
superior relaxation to 80% of the pre-contraction with phenyleph-
rine were considered functional endothelium. Rings with relaxa-
tion less than 10% were considered without functional
endothelium. Rings with relaxation of between 10 and 80% of the
experimental protocols were discarded. After a stabilization period
and veriﬁcation of functional endothelium, TistH was dissolved in
saline and added in increasing concentrations (1.0  1010 to
1.0  105 M) and cumulative concentrations to obtain a concen-
trationeresponse curve. The results are expressed assuming the
phenylephrine-induced contraction is 100% and resting tension is
equal to 0%.
2.13. ACE inhibition
The angiotensin-converting enzyme assays were conducted in a
7.0 pH buffer (ﬁnal volume 100 mL) containing 1.0  101 M
TriseHCl, 6.0 102 MNaCl and 1.0 105M ZnCl2, using Corning®
96 well plates and the peptide substrate, Abz-FRK(Dnp)PeOH, at a
ﬁnal concentration of 4  106 M (Km value) (Araujo et al., 2000).
Four concentrations of TistH, captopril and BPP Xc were used;
1.0  105, 1.0  106, 1.0  108 and 1.0  109 M. The reactions
occurred at 37 C andwere initiated by the addition of 50 ng of ACE.
The reactions were monitored (ﬂuorescence at lEM 420 nm and lEX
320 nm) in a ﬂuorescence spectrophotometer (Victor 3™ Per-
kineElmer, Boston, MA, USA) (Araujo et al., 2000). All assays were
performed in triplicate and the results were expressed as ACE re-
sidual activity (%).
2.14. Statistical analyses
All statistical analyses were performed using GraphPad Prism (v.
5.0, GraphPad Software, Inc.). Results were expressed as
mean ± standard error of the mean (e.p.m.). The comparison be-
tween groups was performed using unpaired “t” test or ANOVA
(One-Way) followed by Tukey's post-test. The comparison between
the points of the concentrationeresponse curves was performed by
ANOVA (two-way) followed by Bonferroni's post-test. The differ-
ence between means was considered signiﬁcant when p < 0.05.3. Results and discussion
3.1. Primary structure
The primary structure of TistH (ADMDFTGIAESIIKKI-
KETNAKPPA) shows 25 amino acid residues, the absence of
cysteine, as well as the presence of an N-terminal alanine (Ala) and
the triplet Pro-Pro-Ala at the C-terminal region. The absence of
cysteine and the presence of the triplet was also observed for
TsHpt-I and TsHpt-II peptides puriﬁed from scorpion venom of
T. serrulatus (Verano-Braga et al., 2008). A different structure was
observed for the ﬁrst BPP puriﬁed from the venom of T. serrulatus
called Peptide T because it lacks the two prolines at the C-terminal
region observed in the studied BPPs (Ferreira et al., 1993). Another
difference in the TistH structurewhen comparedwith BPPs isolated
from snake venom of Bothrops, with more than seven wastes, is to
replace the alanine residue with isoleucine in triplet (Ianzer et al.,
2004) (Fig. S1). The structural basis for TistH was proposed and
validated by homology modeling and molecular dynamics analysis
with an unprecedented hypotensin puriﬁed from a scorpion venom
study.3.2. Homology modeling, molecular dynamics and semi-empirical
method
The sequence of TistH from T. stigmurus was used for the BLAST
search in order to ﬁnd templates for homology modeling. The
closest homology sequences with resolved three dimensional
structures deposited in the Protein Data Bank are listed here in
increasing order of identity: X-ray structure dihydrofolate reduc-
tase/thymidylate synthase from B. bovis at 2.35 Å resolution (PDB
ID: 3I3R, Chain A, identity 50%); Coecrystal structure of dihy-
drofolate reductase-thymidylate synthase from B. boviswith dUMP,
Ralitrexed and NADP (PDB ID: 3NRR, Chain A, identity 50%);
Structure of S. aureus methicillin resistance factor MecR2 (PDB ID:
4IJA, Chain A, identity 73%); Crystal Structure of an N-terminal
Fragment of SKAP-Hom containing both the Dimerization Domain
and the PH Domain (PDB ID: 1U5E, Chain A, identity 78%) and Triple
mutant SFTAVN (PDB ID: 4J4S, Chain A, identity 88%) (Table 1). All
these models were used in the homology modeling MODELLER
program.
One of the most important steps of homology modeling is the
alignment of the target sequence and the template amino acid se-
quences. The multiple sequence alignment was performedwith the
CLUSTALW and it included the sequences of TistH and the closely
related template sequences (Fig. S1).
The top ﬁve models were selected and are listed in Table 2 along
with the used denominations (Model 1e5). Five models were also
Table 2
The molecular probability density function
(molpdf) values of the top ﬁvemodels generated
by MODELLER program.
Models Molpdf
Model-1 133.23
Model-2 137.22
Model-3 139.70
Model-4 141.32
Model-5 141.94
Fig. 1. Average RMSD values of model-8 and model-10.
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models (model 8 and 10), showed the best scores (Table 3) as
validated by the Ramachandran plot. The Ramachandran plot for
model-8 indicates that 100% of the residues were located in the
most favored regions, while model-10 exhibited 95% of the residues
located in the most favored zones and 5% in allowed regions. The
QMEAN score ranges from 0 to 1, meaning that the values closer to
1 correlated with the best quality of the model (Benkert et al.,
2008). Model-8 and model-10 achieved reasonable scores of
0.534 and 0.588 respectively. The two models have the same
molprobity score and percentile value. So, the top two models,
model-8 and model-10, were then subjected to molecular dy-
namics with different force ﬁelds. Fig. S2 shows the RMSD plots of
model-8 (A, C and E) and model-10 (B, D and F). At the end of the
50 ns simulation period, the models exhibited an average RMSD
value of 0.022 nm (Fig. 1), indicating a stable behavior for both
models. Since RMSD values from both models showed no signiﬁ-
cant difference, this parameter has not been able to specify the
most thermodynamically stable model. The electronic and ther-
modynamic properties of the models were also calculated by the
quantum-mechanical PM6 method (Table 4). The values of elec-
tronic energy (Ee) of model-8 indicate that this model is more
stable using the GROMOS96 43a1 force ﬁeld in molecular dynamics
simulations, while the value of heat of formation (DHf) suggests
that model-8, using CHARMM force ﬁeld, results in a stable struc-
ture. For model-10, the simulation with the GROMOS force ﬁeld
results in a more stable geometry according to the value of Ee
(9.13  105 eV), while the value of DHf (5.09  103 kJ/mol) in-
dicates that the AMBER is the most suitable force ﬁeld for model-10
as it presents the highest negative value. Comparing the values of Ee
and DHf between models, the model-10 with GROMOS has the
lowest value of Ee and the highest negative DHf value using the
AMBER force ﬁeld. No differences were found in the values of total
energy (ET). Therefore, simulations using GROMOS96 43a1 and
AMBER-03 force ﬁelds resulted in more stable structures using the
model-10, which can now be considered themost reliable structure
for TistH.
Fig. 2 shows the ﬁnal three-dimensional structures after 50 ns
simulation time of TistH using AMBER (Fig. 2A), and GROMOSTable 3
Values of residues in most favored regions (RMFR) and residues in additional
allowed regions (RAAR), in %, from Ramachandran plot. QMEAN and Molprobity
scores and percentile value of model-8 and model-10.
Models RMFR RAAR QMEAN score Molprobity scorea Percentileb
Model-8 100 0 0.534 1.65 91st
Model-10 95 5 0.588 1.65 91st
a MolProbity score combines the clashscore, rotamer, and Ramachandran evalu-
ations into a single score, normalized so as to be on the same scale as X-ray
resolution.
b 100th percentile is the best among structures of comparable resolution; 0th
percentile is the worst. For clashscore, the comparative set of structures was
selected in 2004, for MolProbity score, in 2006.(Fig. 2B). The single a-helix secondary structure is the main reason
for its stability reﬂected in the aforementioned RMSD plots while
only a small portion of the peptide has a random structure. Mo-
lecular modeling can also contribute to the elucidation of the
mechanism of action of TistH in blood pressure, since it is known
that proline residues present in the primary structure are impor-
tant for anti-hypertensive activity (Morais et al., 2013; Verano-
Braga et al., 2010). The three-dimensional structure helps to un-
derstand how prolines 23 and 24 (highlighted in blue and brown,
respectively, in Fig. 2) can operate in the peptide's mode of action,
since these amino acids are strategically located in a region of non-
deﬁned secondary structure and thus have a greater mobility giving
these amino acids a key role in the anti-hypertensive activity.
3.3. Hemolytic activity hypotensin
The horse erythrocytes were not hemolyzed as seen by the
hemolytic assay microplate, where the absence and presence of
increasing concentrations of TistH were tested for 120min (Fig. S3).
Similar results were observed for the peptide puriﬁed TsAP1 from
the venom of the scorpion T. serrulatus, which showed low hemo-
lytic activity (6.48%) at the highest concentration tested
(160  106 M). The TsAP2 peptide puriﬁed from T. serrulatus
showed 100% hemolysis at concentrations tested (80  106,
120  106 and 160  106 M) (Guo et al., 2013). The cytotoxicity
results obtained from TistH are indicative of low toxicity. TistH was
evaluated for the ability to potentiate the action of bradykinin,
vasorelaxant activity and ACE inhibition.
3.4. Bradykinin-potentiation effect on blood pressure of
anaesthetized rat
Fig. 3 shows the ability of TistH to potentiate the action in the
BK. TistH presented a hypotensive response independent to the
administration of BK. A similar response was observed only for the
peptide TsHpt-I puriﬁed from T. serrulatus scorpion venom and its
synthetic analogues TsHpt-I[17-25], TsHpt-I[KPPA], TsHpt-I[KPP] and
TsHpt-I[KP] and for BPP (Phypo Xa) isolated from the skin secretion
of frog Phyllomedusa hypochondrialis (Conceiç~ao et al., 2007;
Verano-Braga et al., 2010, 2008). TistH was able to potentiate the
hypotensive response of BK for 120min. The enhancing effect of the
BK by BPPs isolated from snake venomhas been associatedwith the
presence of two proline residues at the C-terminal region (Ferreira
et al., 1970; Ianzer et al., 2004; Pimenta et al., 2007; Wermelinger
et al., 2005), as well as the family of BPPs isolated from the
venom of the scorpionT. serrulatus (Verano-Braga et al., 2010, 2008)
and the family of BPP isolated from the skin secretion of frog P.
hypochondrialis (Conceiç~ao et al., 2007). The potentiating effect of
BK by TistH was evaluated at two concentrations (400 mg/kg and
Table 4
Values of electronic energy (Ee), total energy (ET) [in electronvolt (eV)] and heat of formation (DHf) of model-8 and model-10.
Model-8 Model-10
Ee  105 (eV) ET  104 (eV) DHf  103 (kJ/mol) Ee  105 (eV) ET  104 (eV) DHf  103 (kJ/mol)
AMBER 8.72 3.39 4.95 8.95 3.39 5.09
CHARMM 8.75 3.39 5.01 8.94 3.39 4.68
GROMOS 8.89 3.39 4.00 9.13 3.39 3.72
Fig. 2. Three-dimensional structures after 50 ns of molecular dynamics of TistH using
AMBER-03 (A) and GROMOS96 43a1 (B) force ﬁelds. The residues Pro23 and Pro24 are
highlighted in blue and brown, respectively. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Assay potentiation of bradykinin (BK). A) Intravenous injection of a single dose
of captopril (150 mg/kg); B) Intravenous injection of a single dose of TistH (400 mg/kg);
C) Intravenous injection of a single dose of TistH (600 mg/kg). D Blood Pressure ¼ Blood
Pressure basal e Blood Pressure after BK. *P < 0.05; **P < 0.01; ***P < 0.001 comparing
values of BK (3 mg/kg) before injection of TistH (n ¼ 5).
R.J.A. Machado et al. / Toxicon 101 (2015) 11e1816600 mg/kg). A standard drug captopril was used as a positive control
of the potentiating effect of BK (Fig. 3A). TistH, when administered
at a concentration of 400 mg/kg, had no signiﬁcant effect when
compared with the value of BK (3 mg/kg) before administration of
TistH (Fig. 3B). A signiﬁcant potentiating effect of BK was observed
at a concentration of 600 mg/kg TistH compared with the control.
This effect was observed at 10 min and was maintained until
120 min (Fig. 3C). These results suggest that TistH identiﬁed that
the venom of the scorpion T. stigmurus is similar to the BPP family
and the family of hypotensin venom T. serrulatus.
3.5. Mesenteric artery rings assay
Aiming to investigate the putative vasorelaxant effect induced
by TistH, we constructed a dose response curve for different doses
of TistH applied to mesenteric artery rings preparation with or
without functional endothelium. The vasorelaxant effect elicited by
the hypotensin showed a dose-dependent manner (Fig. 4A). The
relaxant effects elicited by TistH (Emax) were 36.91 ± 3.13% and
17.68 ± 2.87% for vessels with (Eþ) or without (E) endothelium,
respectively. The Emax value of 36.91 ± 3.13% for TistHwas superior
to the values observed by Verano-Braga et al. (2008) for TsHpt-I
peptide and its synthetic analog TsHpt-I[17-25] with respective
Emax values of 27% and 18.8% in aorta. In contrast, in the rings
without endothelium vasorelaxant activity was abolished with
values of 2.88% ± 5.05 and 2.35% ± 2.39, respectively.
3.6. Concentration-response curve with blocked L-NAME
To investigate the mechanisms underlying the vasorelaxant ef-
fect in mesenteric artery rings with endothelium, experiments
were conducted in the presence of L-NAME (1  106 M), an in-
hibitor of nitric oxide synthase (NOS). In the presence of L-NAME
the vasorelaxant activity was signiﬁcantly reduced (Fig. 4B). Thisreduction in the presence of L-NAME was also observed in studies
by Verano-Braga et al. (2008, 2010). These data suggest that the
mechanisms underlying TistH have an effect on artery resistance
and involve the release of endothelium-derived nitric oxide, similar
to the mechanism proposed for the Hypotensins family from the
venom of the T. serrulatus scorpion (Verano-Braga et al., 2010,
2008).3.7. ACE inhibition assay
The ﬁrst published work with BPPs suggested that these pep-
tides potentiate the effects of BK and promote hypotension by
inhibiting ACE (Ferreira et al., 1970; Ondetti et al., 1971). In order to
ascertainwhether the cardiovascular effects induced by TistH could
result from the inhibition of ACE, an in vitro assay was performed
Fig. 4. Vasorelaxant effects of TistH. A) Vasorelaxant effects of TistH in mesenteric artery rings from Wistar rats containing (Eþ) or lacking functional endothelium (E); B)
Vasorelaxant effects of TistH in mesenteric artery rings from Wistar rats incubated or not with L-NAME. *p < 0.05 vs Functional endothelium.
R.J.A. Machado et al. / Toxicon 101 (2015) 11e18 17using increasing concentrations of TistH. To act as positive controls,
captopril and BPP Xc, which are potent ACE inhibitors, were used. It
can be seen from the data that the TistH did not inhibit ACE activity
at all tested concentrations (Fig. 5). Recently, it was reported that
TsHpt-I peptide and its synthetic analogues TsHpt-I[17-25], TsHpt-
I[KPP] and TsHpt-I[PPA] from the venom of T. serrulatus do not inhibit
ACE activity in different tested concentrations (Verano-Braga et al.,
2010, 2008). Similar results were observed for some Bj-BPPs (BK
potentiating peptides from the venom of B. jararaca), which
showed antihypertensive activity independent of ACE inhibition
in vitro (Ianzer et al., 2007). Therefore, although ACE inhibition
appears to be the main mechanism of action for antihypertensive
drugs, other distinct mechanisms have been studied for new classes
of peptides that seem to be independent of ACE inhibition.4. Conclusions
An unprecedented hypotensin identiﬁed in T. stigmurus scorpion
venom with a three-dimensional structure solved by homology
modeling, was able to potentiate the action of BK and induce
relaxation in mesenteric artery rings, independent of ACE inhibi-
tion andwithout displaying cytotoxicity. These results contribute to
a better understanding of the use of these peptides in the treatment
of hypertension. Furthermore, the present study contributes to the
better understanding of the mechanisms underlying the action of
these peptides, aiming to develop new classes of antihypertensive
drugs that will expand the range of therapeutic agents available to
control hypertension.Fig. 5. ACE inhibition in vitro assay. Inhibition of ACE activity by captopril, BPP Xc and
TistH in different concentrations (1.0  105, 1.0  106, 1.0  108 and 1.0  109 M).
Captopril and BPP Xc were used as positive controls. *P < 0.05 comparing to 100% ACE
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